Medication info
Griffin Tablet 30 mg (Pioglitazone Hydrochloride)

Griffin Tablet 30 mg (Pioglitazone Hydrochloride)

Prescription medicationTablet
Ingredient · strength
Pioglitazone Hydrochloride›33.06mg / 1 tablet
Manufacturer / importer
Samik Pharmaceutical Co., Ltd.
Appearance
White round tablet
Packaging
Bottle packaging - 30 tablets/bottle, Bottle packaging - 100 tablets/bottle
Approval status
Active

MFDS item code 201905085 · Approved 2019.07.22 · Insurance code 644004270

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults · Children
Adult dosage
This medicine is administered orally once daily, with or without food. Glycated hemoglobin reflects blood glucose levels over the preceding 2 ~ 3 months. Clinically, this medicine should be administered for an adequate period to assess changes in glycated hemoglobin (at least 3 months), provided that glycemic control in patients with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at a dose of 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled with diet and exercise. If the initial dose of this medicine is not sufficiently effective, the dose may be increased to a maximum of 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient experiences symptoms of hypoglycemia, the dose of the sulfonylurea should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted due to symptoms of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when initiating combination therapy with this medicine. However, the insulin dose may be reduced by 10 ~ 25 % if a patient receiving this medicine in combination with insulin experiences symptoms of hypoglycemia or if the plasma glucose concentration decreases to 100 mg/dL or below. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment.
Children's dosage
Administration is not recommended in children under 18 years of age because there is no experience with its use.

Ingredients

Manufacturer
Samik Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Abnormal blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used as an adjunct to dietary control and exercise to assist in blood sugar control for patients with type 2 diabetes. It can be used alone or in combination with other blood sugar-lowering agents such as sulfonylureas, metformin, or insulin when there is no effect from these agents alone. Additionally, it is important for patients with type 2 diabetes to also receive nutritional counseling and, if necessary, to engage in weight loss and exercise. This lifestyle adjustment coupled with medication will greatly aid not only in initial treatment but also in ongoing blood sugar management. This medication is used to improve healthy blood sugar control.

Dosage and Administration

Adult dosage

This medicine is administered orally once daily, with or without food. Glycated hemoglobin reflects blood glucose levels over the preceding 2 ~ 3 months. Clinically, this medicine should be administered for an adequate period to assess changes in glycated hemoglobin (at least 3 months), provided that glycemic control in patients with diabetes does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at a dose of 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled with diet and exercise. If the initial dose of this medicine is not sufficiently effective, the dose may be increased to a maximum of 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea; the initial dose is 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and schedule. However, if the patient experiences symptoms of hypoglycemia, the dose of the sulfonylurea should be reduced. 2) Metformin: This medicine may be administered in combination with metformin; the initial dose is 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and schedule. It is unlikely that the metformin dose will need to be adjusted due to symptoms of hypoglycemia during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when initiating combination therapy with this medicine. However, the insulin dose may be reduced by 10 ~ 25 % if a patient receiving this medicine in combination with insulin experiences symptoms of hypoglycemia or if the plasma glucose concentration decreases to 100 mg/dL or below. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment.

Children's dosage

Administration is not recommended in children under 18 years of age because there is no experience with its use.

Precautions

This medication is used for the treatment of type 2 diabetes and helps improve insulin resistance to aid in blood sugar control. This medication may place a burden on the heart, so patients with heart failure or a history of heart failure should not use it. During use, careful observation is necessary for symptoms of heart failure such as sudden weight gain or shortness of breath. Patients with active bladder cancer or a history of bladder cancer should also not take this medication, and it is advisable not to administer it to patients with severely impaired liver or kidney function. Patients with diabetic ketoacidosis, type 1 diabetes, women who are pregnant or may become pregnant, and patients with lactose intolerance should not use this medication. This medication may cause fluid retention, so those with edema or heart disease should use it cautiously, and especially premenopausal women need appropriate contraception as ovulation may be stimulated, increasing the risk of pregnancy. Routine monitoring of blood sugar, liver function, weight, edema, and symptoms of heart failure is essential during treatment. When used in conjunction with other diabetes medications or insulin, there is an increased risk of hypoglycemia, and adjustments to the doses of the co-administered medications may be necessary. Since this medication is metabolized in the liver, the blood concentration may change when taken with certain other medications; thus, it is important to discuss any concomitant medications with a healthcare professional. The safety of this medication during pregnancy has not been established, so it should only be used in special cases, and breastfeeding women should consult their doctor to decide on its use. Elderly patients may use this medication, but it should be administered with caution, and any side effects should be carefully monitored. In cases of overdose, there may not be specific symptoms, but appropriate treatment should be sought immediately. The safety and efficacy of this medication in children have not been established, so it is not recommended for use in this population. During the course of treatment, patients should strictly adhere to the prescribed dosage according to the physician's instructions, and if a dose is missed, they should not take double the amount the next day. Possible side effects include weight gain, edema, headache, upper respiratory infection, hypoglycemia, urinary tract infection, low back pain, dizziness, diarrhea, elevated creatine kinase (CK) levels, hypertension, itching, chest pain, fatigue, weakness, indigestion, nausea, discomfort in the chest, trembling, chills, gastrointestinal disorders, epigastric discomfort, numbness, trembling, muscle stiffness, discomfort in the head, elevated liver enzymes, hives, eczema, joint pain, knee abnormalities, and arm pain.

Side effects

  • Congestive heart failure
  • heart failure
  • fluid retention
  • edema
  • upper respiratory infection
  • headache
  • sinusitis
  • myalgia
  • pharyngitis
  • abdominal distension
Show 54 more
  • weight gain
  • hypoglycemia
  • urinary tract infection
  • back pain
  • dizziness
  • diarrhea
  • elevated serum creatine kinase
  • hypertension
  • cardiac dysfunction
  • orthostatic hypotension
  • palpitations
  • stroke
  • sexual dysfunction
  • myocardial infarction
  • increased blood sugar
  • loss of appetite
  • constipation
  • upper abdominal pain
  • chest pain
  • fatigue
  • weakness
  • dyspepsia
  • nausea
  • dyspnea
  • itching
  • chest discomfort
  • tremors
  • chills
  • gastrointestinal disease
  • abdominal pain
  • epigastric discomfort
  • numbness
  • muscle rigidity
  • head discomfort
  • increased liver enzymes
  • worsening of liver disease
  • urticaria
  • eczema
  • arthralgia
  • knee abnormalities
  • arm weakness
  • proteinuria
  • increased serum creatinine
  • anxiety
  • insomnia
  • drowsiness
  • simplex herpes
  • blurred vision
  • back pain
  • macular edema
  • fracture
  • liver failure
  • decreased vision
  • bladder cancer

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a tightly sealed container that blocks light. Additionally, care should be taken to prevent moisture exposure, and it is important to maintain storage temperatures between 1°C and 30°C.

Appearance and packaging

Appearance

White round tablet

Package unit

Bottle packaging - 30 tablets/bottle, Bottle packaging - 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.